Quantitation of Phencyclidine in Urine for SAMHSA-Mandated Workplace Drug Confirmation Testing Using LC-MS/MS

Kristine Van Natta, Marta Kozak, Thermo Fisher Scientific, San Jose, CA

Key Words

SAMHSA, workplace drug confirmation testing, TSQ Quantum Ultra, TraceFinder, PCP, phencyclidine, SOFT-DFSA

Goal

The goal of this work was to develop a specific and robust dilute-and-shoot quantitative method that meets SAMHSA cutoffs for the confirmation of phencyclidine in urine. An additional goal was to have the sample processing method be suitable for all SAMHSA panel compounds to reduce duplicate processing for the different classes of compounds.

Introduction

In the United States, federal employees and public transportation workers are required to pass a preemployment drug screen known as the NIDA5 or SAMHSA panel. The panel is divided into 5 groups: opiates, amphetamines, cocaine (benzoylecgonine), cannabis (THCA) and phencyclidine (PCP). Per SAMHSA requirements, these five groups are screened with immunoassays and, in the past, confirmed by gas chromatography/mass spectrometry (GC/MS). In October 2010, SAMHSA approved the use of liquid chromatography/mass spectrometry (LC/MS) for confirmation of workplace drug testing samples. This note describes the use of LC/MS with a triple-stage quadrupole mass spectrometer to confirm phencyclidine (PCP).

Experimental

Sample Preparation

Urine was spiked with a deuterated internal standard (PCP- d_3) and hydrolyzed with β -glucuronidase. Although PCP does not require hydrolysis, other compounds in the SAMHSA panel such as the opiates and THC do. Adding this step enables all SAMHSA panel compounds to be processed with one method. Methanol was added to the hydrolysis mixture and the resulting mixture was centrifuged. Supernatant was further diluted and subjected to LC/MS confirmatory analysis.

Liquid Chromatography

Chromatographic separations were performed with a Thermo Scientific[™] Accela[™] 600 pump and Accela Open autosampler. The analytical column was a Thermo Scientific Hypersil GOLD aQ[™] column (50 x 4.6 mm, 1.9 µm particle size). The column was maintained at room temperature. The injection volume was 20 µL. Mobile phases A and B consisted of 5 mM ammonium formate with 0.1% formic acid in water (Fisher Chemical HPLC grade, W5) and methanol (Fisher Chemical HPLC grade, A452), respectively. Mobile phase C was acetonitrile/1-propanol/acetone (45:45:10). The total run time was 4 minutes.

Mass Spectrometry

MS analysis was carried out on a Thermo Scientific TSQ Quantum UltraTM triple-stage quadrupole mass spectrometer equipped with a heated electrospray ionization (HESI-II) probe. Two selected-reaction monitoring (SRM) transitions were monitored for both PCP and its deuterated internal standard, PCP- d_s , to provide ion ratio confirmation (IRC). Data was analyzed using Thermo Scientific TraceFinderTM software.

Validation

Standard curves were prepared by fortifying pooled blank human urine with PCP. Quality control (QC) samples were prepared in a similar manner at concentrations corresponding to the lower limit of quantitation (LLQC), low (LQC), middle (MQC), and high (HQC) end of the calibration range. Inter-run variability and robustness were determined by processing six replicates of each QC level along with a calibration curve as outlined in the Sample Preparation section on three different days. Matrix effects were investigated by comparing peak areas of analyte and internal standard prepared in twelve different lots of urine to those of a sample prepared in water.



Results and Discussion

The limit of quantitation (LOQ) for PCP in this method was 5 ng/mL, which exceeds the SAMHSA confirmation requirement of 25 ng/mL as well as the Society of Forensic Toxicology – Drug Facilitated Sexual Assault (SOFT-DFSA) cut-off of 10 ng/mL. Figure 1 shows an SRM chromatogram at the LOQ of 5 ng/mL. Results were linear from 5 to 2000 ng/mL. Figure 2 shows a representative calibration curve. Quality control results for the validation are shown in Table 1. The quality controls showed good precision and accuracy.

Table 1. Statistics for quality controls run during validation

	LLQC 5 ng/mL	LQC 15 mg/mL	MQC 100 ng/mL	HQC 1500 ng/mL
%CV	5.99%	7.53%	4.92%	8.87%
%Bias	-0.674%	-3.99%	-7.18%	2.89%
n	18	18	18	18




Figure 1. Chromatogram of PCP at 5 ng/mL showing quantifying and confirming ions




Figure 2. Representative calibration curve for PCP in urine

Matrix effects

Peak areas of PCP spiked at 10 ng/mL in 12 different lots of urine showed absolute recoveries between 95% and 111% compared to a sample in water, indicating no significant matrix effects. For PCP- d_5 , the absolute recoveries were between 81% and 103%.

Conclusion

- A method with simple dilute-and-shoot sample preparation for the confirmation of PCP in urine was developed.
- This method is suitable for SAMHSA-mandated workplace drug testing confirmation, meeting cutoff requirements within a 4 minute run.
- The sample processing method enables all SAMHSA panels to be processed at once.
- The method showed good linearity across the required calibration ranges.
- Controls indicated good method precision and robustness.
- No matrix effects were observed.

www.thermoscientific.com

©2013 Thermo Fisher Scientific Inc. All rights reserved. ISO is a trademark of the International Standards Organization. All other trademarks are the property of Thermo Fisher Scientific Inc. and its subsidiaries. This information is presented as an example of the capabilities of Thermo Fisher Scientific Inc. products. It is not intended to encourage use of these products in any manners that might infringe the intellectual property rights of others. Specifications, terms and pricing are subject to change. Not all products are available in all countries. Please consult your local sales representative for details.



Europe-Other +43 1 333 50 34 0 Finland/Norway/Sweden +46 8 556 468 00 France +33 1 60 92 48 00 Germany +49 6103 408 1014 India +91 22 6742 9434 Italy +39 02 950 591 Japan +81 45 453 9100 Latin America +1 561 688 8700 Middle East +43 1 333 50 34 0 Netherlands +31 76 579 55 55 New Zealand +64 9 980 6700 Russia/CIS +43 1 333 50 34 0 South Africa +27 11 570 1840



Spain +34 914 845 965 **Switzerland** +41 61 716 77 00 **UK** +44 1442 233555 **USA** +1 800 532 4752

> AN63702_E 01/13S BN0911144

